Editorial: Ovarian cancer targeted medication: PARP inhibitors, anti-angiogenic drugs, immunotherapy, and more, volume II

Editorial: Ovarian cancer targeted medication: PARP inhibitors, anti-angiogenic drugs, immunotherapy, and more, volume II

Saved in:

Bibliographic Details
Main Authors:	Zhi-Bin Wang, De-Hua Liao, Guang Lei, Zhao-Qian Liu, Nayiyuan Wu, Jing Wang
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2025-02-01
Series:	Frontiers in Pharmacology
Subjects:	ovarian cancer targeted medication immunomodulatory drug resistance PARP inhibitors anti-angiogenic drugs
Online Access:	https://www.frontiersin.org/articles/10.3389/fphar.2025.1552652/full
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

PARP Inhibitors in the Treatment of Ovarian Cancer
by: Andrzej Paweł Zuzak, et al.
Published: (2025-02-01)

Repression of PFKFB3 sensitizes ovarian cancer to PARP inhibitors by impairing homologous recombination repair
by: Yinan Xiao, et al.
Published: (2025-01-01)

Opportunities for predictive proteogenomic biomarkers of drug treatment sensitivity in epithelial ovarian cancer
by: Trudy J. Philips, et al.
Published: (2025-01-01)

First-line combination therapy of immunotherapy plus anti-angiogenic drug for thoracic SMARCA4-deficient undifferentiated tumors in AIDS: a case report and review of the literature
by: Xiaoling Wei, et al.
Published: (2025-01-01)

A therapy inactivating the tumor angiogenic factors
by: Cristian Morales-Rodrigo
Published: (2012-11-01)

Poly-ADP ribose polymerase (PARP) inhibitor regimens for platinum-sensitive ovarian cancer in randomized, double-blind, phase III controlled trials: protocol for a systematic review and network meta-analysis
by: Xiaolian Peng, et al.
Published: (2025-01-01)

Structural modeling of NAD+ binding modes to PARP-1
by: N. V. Ivanisenko, et al.
Published: (2017-02-01)

Efficacy of PARPi re-maintenance therapy for recurrent ovarian cancer
by: Yulin Wang, et al.
Published: (2025-01-01)

PARP inhibitors in the treatment of Pancreatic Cancer - A Review of literature
by: Jagoda Niewiadomska, et al.
Published: (2025-01-01)

The Pathogenic Role of Expanded CD8⁺CD28<sup>null</sup> Angiogenic T Cells in ANCA-Associated Vasculitis
by: Haomiao Shen, et al.
Published: (2024-12-01)

DRG2 levels in prostate cancer cell lines predict response to PARP inhibitor during docetaxel treatment
by: Jeong Min Lee, et al.
Published: (2025-01-01)

Simultaneously delivery of functional gallium ions and hydrogen sulfide to endow potentiated treatment efficacy in chemo- and PARPi-resistant ovarian cancer
by: Sangsang Tang, et al.
Published: (2025-02-01)

Immunotherapy in Recurrent Ovarian Cancer
by: Keyao Chen, et al.
Published: (2025-01-01)

Incidence and risk of endocrine and metabolic abnormalities linked to PARP inhibitors in solid tumors: a meta-analysis
by: Shunlian Fu, et al.
Published: (2025-01-01)

Revolutionizing ovarian cancer therapy by drug repositioning for accelerated and cost-effective treatments
by: Edgar Yebran Villegas-Vazquez, et al.
Published: (2025-01-01)

Preclinical evaluation of the potential PARP-imaging probe [carbonyl-11C]DPQ
by: Katarína Benčurová, et al.
Published: (2025-01-01)

Effect of platelet-rich plasma on angiogenic and regenerative properties in patients with critical limb ischemia
by: Hamid Tanzadehpanah, et al.
Published: (2025-03-01)

Addition of PARP1-inhibition enhances chemoradiotherapy and thermoradiotherapy when treating cervical cancer in an in vivo mouse model
by: Marloes IJff, et al.
Published: (2025-12-01)

New insight in immunotherapy and combine therapy in colorectal cancer
by: Kai Ji, et al.
Published: (2025-01-01)

Low dose DNA methyltransferase inhibitors potentiate PARP inhibitors in homologous recombination repair deficient tumors
by: Romain Pacaud, et al.
Published: (2025-01-01)

Peritoneal chemotherapy delivery systems for ovarian cancer treatment: systematic review of animal models
by: Marcelo Simonsen, et al.
Published: (2025-01-01)

Application of Nano-drug Delivery Technology in Overcoming Drug Resistance  in Lung Cancer
by: Yingchun LU, et al.
Published: (2024-11-01)

Patient‐derived acellular ascites fluid affects drug responses in ovarian cancer cell lines through the activation of key signalling pathways
by: Katharina Bischof, et al.
Published: (2025-01-01)

Immunomodulatory effects of polysaccharides from edible fungus: a review
by: Zhenhua Yin, et al.
Published: (2021-07-01)

CDK4/6 inhibitors promote PARP1 degradation and synergize with PARP inhibitors in non-small cell lung cancer
by: Carlos M Roggero, et al.
Published: (2025-02-01)

A new strategy for the treatment of advanced ovarian cancer: utilizing nanotechnology to regulate the tumor microenvironment
by: Zixuan Xiong, et al.
Published: (2025-02-01)

iNOS-Produced Nitric Oxide from Cancer Cells as an Intermediate of Stemness Regulation by PARP-1 in Colorectal Cancer
by: María del Moral-Martinez, et al.
Published: (2025-01-01)

干扰素调节因子5下调PARP-1抑制鼻咽癌细胞的侵袭力
by: 李民英, et al.
Published: (2018-01-01)

PARylation of HMGA1 desensitizes esophageal squamous cell carcinoma to olaparib
by: Xin‐Yuan Lei, et al.
Published: (2024-12-01)

CT-based radiomics predicts HRD score and HRD status in patients with ovarian cancer
by: Yujiao Wu, et al.
Published: (2025-01-01)

PARP‐1 Inhibition Increases Oxidative Stress in Ets‐1‐Expressing MDA‐MB‐231 Breast Cancer Cells
by: Magalie Hervieu, et al.
Published: (2025-01-01)

A comprehensive comparison of PARP inhibitors as maintenance therapy in platinum-sensitive recurrent ovarian cancer: a systematic review and network meta-analysis
by: Shiya Ji, et al.
Published: (2025-01-01)

Multi-stage structure-based virtual screening approach combining 3D pharmacophore, docking and molecular dynamic simulation towards the identification of potential selective PARP-1 inhibitors
by: Mahmoud A. El Hassab, et al.
Published: (2025-02-01)

The impact of heterotopic ovarian tissue transplantation with varied volumes on reproductive endocrine function in oophorectomized rats
by: Nana Tian, et al.
Published: (2024-12-01)

Transcriptome analysis reveals the anticancer effects of fenbendazole on ovarian cancer: an in vitro and in vivo study
by: Xin Wang, et al.
Published: (2024-12-01)

Ovarian Reserve: A Critical Indicator of Female Reproductive Health
by: Julia Ufnal, et al.
Published: (2025-01-01)

Perspectives of pressurized intraperitoneal aerosol chemotherapy in terms of primary ovarian cancer with peritoneal carcinomatosis treatment
by: A. S. Dzasokhov, et al.
Published: (2023-03-01)

A spatial model of tumor-host interaction: Application of chemotherapy
by: Peter Hinow, et al.
Published: (2009-05-01)

Adverse drug events (ADEs) risk signal mining related to eculizumab based on the FARES database
by: Xi-Feng Wang, et al.
Published: (2025-01-01)

Corrigendum: Adverse drug events (ADEs) risk signal mining related to eculizumab based on the FARES database
by: Xi-Feng Wang, et al.
Published: (2025-02-01)